Even occasional treatments carry risk
While nothing has been filed at the writing of this article, the OFA has yet to respond to our inquires on the future of the case, but has since issued a statement from their official Linkedin page: It is made abundantly clear in the statement from the OFA, that they intend to continue their efforts to hold the FDA accountable for what they are claiming "ignores the facts" about the shortages patients are facing
Their study found that NRF2 translocation into the nucleus and NAD(P)H quinone oxidoreductase (NQO1) activity were significantly increased after treatment of astrocytes with tert-butylhydroquinone (tBHQ), resveratrol, or curcumin at 2050 M [159]
Consent for publication No consent is needed, as this manuscript contains no personal data
doi:10.1001/jamainternmed.2013.2720 Smits MM, Van Raalte DH
Senescence-Associated Secretory Phenotype (SASP) and Senotherapy in Aging